SSKI Side Effects
Generic Name: potassium iodide
Note: This document contains side effect information about potassium iodide. Some of the dosage forms listed on this page may not apply to the brand name SSKI.
Some side effects of SSKI may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to potassium iodide: oral solution, oral syrup
Along with its needed effects, potassium iodide (the active ingredient contained in SSKI) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor as soon as possible if any of the following side effects occur while taking potassium iodide:Less common
- joint pain
- swelling of arms, face, legs, lips, tongue, and/or throat
- swelling of lymph glands
- Burning of mouth or throat
- headache (severe)
- increased watering of mouth
- irregular heartbeat
- metallic taste
- numbness, tingling, pain or weakness in hands or feet
- soreness of teeth and gums
- sores on skin
- symptoms of head cold
- unusual tiredness
- weakness or heaviness of legs
Some side effects of potassium iodide may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:Less common
- nausea or vomiting
- stomach pain
For Healthcare Professionals
Applies to potassium iodide: compounding powder, oral liquid, oral solution, oral tablet
Endocrinologic side effects have included both hyper- and hypothyroidism. By inhibiting the release of thyroid hormone from the thyroid gland, iodide can cause goiter and hypothyroidism. This has been called the Wolff-Chaikoff effect, occurring in approximately 4% of patients, and may be more likely in patients with cystic fibrosis (CF). Iodide may induce hyperthyroidism, called the Jod-Basedow effect, when given to patients with preexisting iodide deficiency or autonomous, "hot" thyroid nodules. Iodide can cause parotid gland swelling.
In one study of 55 patients with CF who were treated with iodides, 47 developed goiters, and 14 had clinical or laboratory evidence of hypothyroidism. In 2 of the 14 hypothyroidism occurred in the absence of a goiter. Subsequent data are consistent with the possibility that peripheral deiodination of T4 to T3 may be impaired in these patients. Failure to appreciate this can lead to the erroneous diagnosis of congenital hypothyroidism in some patients with CF.
The pathogenesis of vegetating iododerma is not clear, may be idiosyncratic, and appears to involve a hyperinflammatory response. Iodides appear to increase the movement of polymorphonuclear leukocytes (PMNLs) into areas of inflammation, enhancing the inflammatory response. Since PMNLs are known to increase connective tissue proliferation, iodides could convert an area of inflammation into an area of proliferative tissue, providing and explanation for proliferative iododermas.
Dermatologic side effects have included iododerma in approximately 1% of patients. Iododerma is a term used describe a wide range of dermatologic side effects of KI that typically affect the face, neck, back and upper extremities. Iododerma may present as acneiform vesiculobullous, vesicular, pustular, hemorrhagic or urticarial lesions. The incidence of skin eruptions associated with the use of KI in inpatients from the Boston Collaborative Surveillance Program was less than 0.6%. Rare cases of urticaria, angioedema, polymyalgia, and life-threatening systemic reactions have been associated with the use KI in patients with underlying connective tissue disorders.
Rare cases of severe, ulcerative, vegetating iododerma in patients with underlying polyarteritis nodosa, arthritis, lymphoma, subacute glomerulonephritis, multiple myeloma, dermal vasculitis or hypocomplementemia have been reported.
Hypersensitivity side effects have included rash, fever, eosinophilia, jaundice, pruritus, angioedema, lymphadenopathy, arthralgia, bronchospasm, submucosal hemorrhage and periarteritis nodosa-type reactions. Bullous iododerma appear to be an allergic reaction, and can be fatal. Other known hypersensitivity reactions to iodides include hematuria, proteinuria, and pulmonary edema. Predisposing risk factors for hypersensitivity reactions appear to include some underlying connective tissue disorders.
Gastrointestinal side effects have included "upset stomach" in 10% to 40% of patients, depending on the dose. Other common GI complaints include an unpleasant, "brassy" taste, throat or retrosternal burning, sore gums, and salivation. In rare cases and in cases of overdose, esophagitis and gastritis have been reported.
Iodide may interfere with certain autoanalyzer measurements of serum chloride, resulting in falsely elevated values. The "true" anion gap in some cases can, therefore, be higher than the calculated anion gap. "Hyperchloremic acidosis" has been associated with ingestion of KI. In some cases of KI overdose, the anion gap was due to the presence of high serum levels of lactic acid.
Metabolic side effects have included metabolic acidosis following KI overdose.
Renal side effects have included acute renal failure secondary to tubular necrosis following KI overdose.
Hematologic side effects have included rare reports of hemolytic anemia, and appear to be limited to cases of overdose.
Immunologic side effects have included rare cases of systemic granulomatous vasculitis.
A 37-year-old female with Sweet's syndrome was successfully treated with potassium iodide. Within 12 days after beginning therapy, however, she developed malaise, diminished vision, hypertension, rash, and fever. Physical and laboratory findings revealed new renal insufficiency, bilateral papillitis on retinal examination, and leukocytoclastic vasculitis per skin biopsy. Renal biopsy and renal and mesenteric angiography were normal. The patient's signs and symptoms resolved over 11 months with the addition of oral prednisolone therapy.
More about SSKI (potassium iodide)
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.